Clal Biotechnology | CBI - Operating Expenses


Clal Biotechnology reported ILS5.15M in Operating Expenses for its fiscal quarter ending in December of 2022.





Operating Expenses Change Date
Arca Biopharma USD 36.43M 2M Mar/2026
aTyr Pharma USD 2.55M 126.72K Jun/2026
Bio Path USD 297K 191K Mar/2026
Brainstorm Cell Therapeutics USD 2.05M 198K Mar/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.44M 246K Jun/2026
Immunic USD 23.33M 2.67M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
RedHill Biopharma USD 5.51M 1.08M Jun/2024
TherapeuticsMD USD 1.41M 50K Jun/2024